Literature DB >> 21801173

Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy.

Ahmad Nizam1, Krishna Mylavarapu, Dwithiya Thomas, Klara Briskin, Brenda Wu, Deepak Saluja, Stephen Wong.   

Abstract

Dose-dependent PR interval prolongation has been reported in preclinical studies of lacosamide (LCM), a recently U.S. Food and Drug Administration (FDA)-approved antiepileptic drug (AED). Here we report a case of second-degree atrioventricular block (AV) block caused by the addition of LCM to other AEDs known to prolong the PR interval, resulting in hypotension and bradycardia, with consequent seizure exacerbation. The patient recovered completely after withdrawal of LCM. This case demonstrates the need for caution and interval cardiac testing when adding LCM to other AEDs known to prolong the PR interval. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21801173     DOI: 10.1111/j.1528-1167.2011.03212.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  21 in total

1.  Safe Treatment of Seizures in the Setting of HIV/AIDS.

Authors:  Omar Siddiqi; Gretchen L Birbeck
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

2.  Block of human cardiac sodium channels by lacosamide: evidence for slow drug binding along the activation pathway.

Authors:  Ging Kuo Wang; Sho-Ya Wang
Journal:  Mol Pharmacol       Date:  2014-02-21       Impact factor: 4.436

Review 3.  Novel medications for epilepsy.

Authors:  Cinzia Fattore; Emilio Perucca
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

4.  Lacosamide: a Study of Exposures Reported to US Poison Centers over a 9-Year Period.

Authors:  John Teijido; Derek Kempf; Elizabeth Laubach; Amy Zosel; Douglas Borys
Journal:  J Med Toxicol       Date:  2019-07-08

Review 5.  The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience.

Authors:  Sebastian Bauer; Laurent M Willems; Esther Paule; Christine Petschow; Johann Philipp Zöllner; Felix Rosenow; Adam Strzelczyk
Journal:  Ther Adv Neurol Disord       Date:  2016-11-29       Impact factor: 6.570

6.  Use of lacosamide in children with refractory epilepsy.

Authors:  Marcia L Buck; Howard P Goodkin
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07

7.  Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

Authors:  Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

Review 8.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 9.  Lacosamide: A Review in Focal Seizures in Patients with Epilepsy.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

Review 10.  Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy.

Authors:  Martin J Brodie
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.